Under the Symbol:
OptimizeRx to Present at 11th Annual LD Micro Main Event on December 4-6, 2018
Wednesday, November 28, 2018 2:06 PM
ROCHESTER, MI / ACCESSWIRE / November 28, 2018 / OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health messaging for the pharmaceutical industry, has been invited to present at 11th Annual LD Micro Main Event institutional investor conference being held on December 4-6, 2018 at the Luxe Sunset Bel Air Hotel in Bel Air, California.
William Febbo, CEO of OptimizeRx, is scheduled to present on Tuesday, December 4, at 1:30 p.m. Pacific time, with one-on-one meetings with institutional analysts and investors. He will discuss OptimizeRx's record Q3 results, recent acquisition of CareSpeak Communications and its growing network that reaches more than half of the ambulatory patient market in the U.S. The company's largest point-of-care network that helps improve medication affordability, adherence and care outcomes.
The presentation will be also webcast live and available for replay here and via the investor relations section of the company's website at www.optimizerx.com.
OptimizeRx recently reported record third quarter of 2018 results, its eighth consecutive quarter of revenue growth and second consecutive quarter of profitability. Net revenue increased 75% to a record $5.4 million, gross margin improved from 45.1 percent to 58.1 percent, and net income of $245,000 or $0.02 per diluted share.
The LD Micro Main Event is one of the nation's largest independent conferences for micro-cap companies, with over 250 names presenting to more than 1,500 attendees. The conference will also feature variety of speakers and panelists discussing topics of interest to investors and issuers, as well as evening social events.
To schedule a one-on-one meeting with OptimizeRx, you may submit your request online via the link provided upon registration. To register for the conference, contact David Scher at [email protected] or visit www.ldmicro.com/events. For any questions about the company, contact Ron Both of CMA at (949) 432-7557 or submit your request here.
View OptimizeRx's LD Micro profile here: https://www.ldmicro.com/profile/OPRX
Profiles powered by LD Micro - News Compliments of Accesswire
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe. For more information about LD Micro, go to www.ldmicro.com/events.
OptimizeRx® (NASDAQ: OPRX), a digital health company, connects pharmaceutical companies to patients and providers, offering greater affordability, adherence and brand awareness at the point-of-care. As the nation's largest point-of-prescribe promotional platform for the pharmaceutical industry, OptimizeRx provides a direct channel for pharma companies to communicate with healthcare providers right within their workflow. The cloud-based solution supports patient adherence to medications with real-time access to financial assistance, prior authorization, education and critical clinical information. OptimizeRx provides more than half of the ambulatory patient market with access to these benefits through leading EHR platforms like Allscripts, Amazing Charts and Quest. The company's mobile messaging platform also supports direct, real-time communication to patients for improved medication adherence, affordability, and healthcare outcomes. For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Doug Baker, CFO
Tel (248) 651-6568 x807
Media Relations Contact
Nicole Brooks, Innsena Communications
Investor Relations Contact
Ron Both, CMA
Tel (949) 432-7557
SOURCE: OptimizeRx Corp.